• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    9/22/23 1:31:09 PM ET
    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email

    Gainers

    • Myomo (AMEX:MYO) stock moved upwards by 20.1% to $1.25 during Friday's regular session. Trading volume for Myomo's stock is 192.5K as of 13:30 EST. This is 35.6% of its average full-day volume over the last 100 days. The company's market cap stands at $33.1 million.
    • Cellectar Biosciences (NASDAQ:CLRB) stock rose 18.72% to $2.6. As of 13:30 EST, Cellectar Biosciences's stock is trading at a volume of 168.2K, which is 27.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.3 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock increased by 17.56% to $0.12. The current volume of 282.4 million shares is 996.7% of Avalo Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $2.4 million.
    • Shattuck Labs (NASDAQ:STTK) shares increased by 16.99% to $1.79. Trading volume for this security as of 13:30 EST is 228.0K, which is 1203.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $76.0 million.
    • Connect Biopharma Hldgs (NASDAQ:CNTB) shares rose 16.54% to $0.76. As of 13:30 EST, Connect Biopharma Hldgs's stock is trading at a volume of 105.3K, which is 299.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.8 million.
    • Synaptogenix (NASDAQ:SNPX) shares moved upwards by 15.47% to $0.32. As of 13:30 EST, this security is trading at a volume of 11.1 million shares, making up 1141.0% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.

    Losers

    • Morphic Holding (NASDAQ:MORF) stock decreased by 27.1% to $37.5 during Friday's regular session. As of 13:30 EST, Morphic Holding's stock is trading at a volume of 3.7 million, which is 961.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 billion.
    • VolitionRX (AMEX:VNRX) stock declined by 24.92% to $0.77. As of 13:30 EST, VolitionRX's stock is trading at a volume of 1.2 million, which is 970.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $59.8 million.
    • Pharming (NASDAQ:PHAR) stock decreased by 19.31% to $12.89. The company's market cap stands at $850.0 million.
    • Applied Molecular (NASDAQ:AMTI) shares fell 16.72% to $0.17. Trading volume for this security as of 13:30 EST is 2.1 million, which is 227.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.6 million.
    • Seelos Therapeutics (NASDAQ:SEEL) stock declined by 15.32% to $0.16. Trading volume for Seelos Therapeutics's stock is 19.6 million as of 13:30 EST. This is 872.0% of its average full-day volume over the last 100 days. The company's market cap stands at $20.5 million.
    • T2 Biosystems (NASDAQ:TTOO) stock decreased by 14.19% to $0.25. As of 13:30 EST, T2 Biosystems's stock is trading at a volume of 54.7 million, which is 48.4% of its average full-day volume over the last 100 days. The company's market cap stands at $82.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTI
    $AVTX
    $CLRB
    $CNTB

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Shattuck Labs Inc.
    $STTK
    1/28/2026$15.00Overweight
    Piper Sandler
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Shattuck Labs Inc.
    $STTK
    12/1/2025$6.00Neutral → Buy
    H.C. Wainwright
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Shattuck Labs Inc.
    $STTK
    9/8/2025$4.00Outperform
    Wedbush
    More analyst ratings

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    SEC Filings

    View All

    SEC Form 10-K filed by Shattuck Labs Inc.

    10-K - Shattuck Labs, Inc. (0001680367) (Filer)

    3/5/26 6:28:44 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Shattuck Labs, Inc. (0001680367) (Filer)

    3/5/26 6:23:11 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

    3/4/26 7:23:46 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Shattuck Labs with a new price target

    Piper Sandler initiated coverage of Shattuck Labs with a rating of Overweight and set a new price target of $15.00

    1/28/26 7:19:49 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    GC - Volition Diagnostics Plummer Nicholas covered exercise/tax liability with 5,867 shares, decreasing direct ownership by 1% to 414,270 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:30:25 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard covered exercise/tax liability with 3,321 shares, decreasing direct ownership by 1% to 277,941 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:31:18 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Commercial Officer Forterre Gael covered exercise/tax liability with 2,283 shares, decreasing direct ownership by 0.67% to 336,589 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:30:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

    Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights. "

    3/5/26 6:15:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

    On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31

    3/4/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About

    3/3/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

    HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas

    1/20/26 8:25:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Financials

    Live finance-specific insights

    View All

    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

    On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31

    3/4/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will

    2/26/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AVTX
    $CLRB
    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    11/14/24 7:32:44 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care